Pharvaris N.V.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Large accelerated filer
State of Incorporation
Netherlands
Country
Netherlands
Business Address
J.H. OORTWEG 21, LEIDEN, ,
Mailing Address
J.H. OORTWEG 21, LEIDEN, ,
Phone
31 (0)71 203 6410
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 20-F Foreign company annual report | April 2, 2026 | View on SEC |
| 6-K Foreign company current report | April 2, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
Annual Reports
20-F
April 2, 2026
- Advancing lead drug candidate deucrictibant through late-stage global clinical trials (CHAPTER-1 and HORIZON).
- Strong cash position of $238.4 million, providing an operational runway into 2026.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.